Grrrr! Another one with no details of value to company
$Amneal Pharmaceuticals(AMRX.US$ Amneal Pharmaceuticals (AMRX) said Tuesday it licensed its upcoming Parkinson's drug IPX203 to Zambon Biotech in the European Union, United Kingdom, and Switzerland.
Amneal's medicine is an oral formulation of the carbidopa-levodopa combo used to treat Parkinson's disease. IPX203 is currently under review in the US.
Zambon will seek regulatory approval and commercialize IPX203 in Europe, Amneal said.
Financial terms of the agreement were not disclosed.
Amneal's medicine is an oral formulation of the carbidopa-levodopa combo used to treat Parkinson's disease. IPX203 is currently under review in the US.
Zambon will seek regulatory approval and commercialize IPX203 in Europe, Amneal said.
Financial terms of the agreement were not disclosed.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
